RORB
ENSG00000198963
Target class
Nuclear receptor
Chromosome
9
- ClinGen gene-disease validity
- Definitive
- Chemical probe available
- No
- Target name
- RORB
- Gene name
- RAR related orphan receptor B
- Gene symbol
- RORB
- Protein name
- Nuclear receptor ROR-beta (Nuclear receptor RZR-beta) (Nuclear receptor subfamily 1 group F member 2) (Retinoid-related orphan receptor-beta)
- RZRB
- NR1F2
- ROR-BETA
- RORβ
- RZR-BETA
- Gene biotype
- Protein coding
- Gene family
- RAR related orphan receptors
- Target class
- Nuclear receptor
- Target type
- Human gene
- Tissues expressed in
- 19
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 17.02
- Tissue specificity (Gini)
- 0.676
- Tissue specificity (tau)
- 0.919
- KEGG gene identifiers
- hsa:6096
- Protein interaction confidence
- 0.873375
- Protein interaction partners
- 16
- R-HSA-383280
- R-HSA-9931509
- End position
- 74693177
- Start position
- 74497335
- Chromosome
- 9
- Strand
- Forward
- Nucleus, nucleoplasm .
- Nucleoplasm
Publication evidence
- PubMed 27352968
- Tissue specificity (tau)
- 0.918697
- Expression inequality (Gini)
- 0.675799
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)
- 17.02
- Brain - Cortex
- 11.32
- Brain - Anterior cingulate cortex (BA24)
- 6.14
- Artery - Tibial
- 5.66
- Prostate
- 4.31
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)17.02
- Brain - Cortex11.32
- Brain - Anterior cingulate cortex (BA24)6.14
- Artery - Tibial5.66
- Prostate4.31
- Brain - Caudate (basal ganglia)4.18
- Brain - Amygdala3.73
- Brain - Hypothalamus3.57
- Brain - Putamen (basal ganglia)3.22
- Brain - Nucleus accumbens (basal ganglia)3.13
- Pituitary2.98
- Cervix - Endocervix1.99
- Adrenal Gland1.99
- Brain - Substantia nigra1.73
- Nerve - Tibial1.62
- Brain - Hippocampus1.61
- Cervix - Ectocervix1.6
- Vagina1.55
- Brain - Cerebellum1.07
- Brain - Cerebellar Hemisphere0.76
- Bladder0.74
- Brain - Spinal cord (cervical c-1)0.73
- Adipose - Visceral (Omentum)0.64
- Adipose - Subcutaneous0.62
- Testis0.58
And 29 more, listed on the interactive page.
Biological processes
- GO:0006355
Cellular components
- GO:0005654
- GO:0004879
- GO:0005515
- GO:1990837
regulation of transcription factor activity
- cell-based: ATG_RORb_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.
- cell-based: ATG_RORb_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.
- cell-based: ATG_RORE_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.
- cell-based: ATG_RORE_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.
Biological samples
- HepG2, cell line
Evidence source
Related records
Trials (172)
- "AIDA" Protocol (LAP 0493)
- 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)
- A Clinical Study Evaluating the Efficacy and Safety of Retinoic Acid in Patients With 15q11-q13 Duplication Syndrome
- A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel
- A Comparative Study of Adapalene Gel,0.3% Versus Tretinoin Emollient Cream, 0.05% for the Treatment of Photoaging
- A Fixed Triple Combination Cream for Solar Lentigines Associated to Cryotherapy
- A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment
- A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS
- A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne
- A Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne Vulgaris
- A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne Vulgaris
- A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris
- A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
- A Study of ATRA in the Treatment of ITP
- A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)
- A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
- A Study of Different Use Regimens Using Two Acne Treatments
- A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products
- A Study to Determine the Safety and Efficacy of Atralin (Tretinoin 0.05%) Gel for the Treatment of Rosacea
- A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma